More on Sanofi (SNY) Q4: Income at Genzyme and emerging markets offsets the expiry of patents...

|About: Sanofi (SNY)|By:, SA News Editor

More on Sanofi (SNY) Q4: Income at Genzyme and emerging markets offsets the expiry of patents and the effect of EU austerity. Sanofi expects 2012 business EPS to fall 12%-15% due to patent loss of Plavix and Avapro, but predicts 5% annual sales growth and faster EPS growth after that to 2015.